| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colorectal Neoplasms | 43 | 2026 | 642 | 6.200 |
Why?
|
| Neoplasms | 21 | 2026 | 457 | 6.090 |
Why?
|
| Early Detection of Cancer | 36 | 2026 | 559 | 5.690 |
Why?
|
| Mass Screening | 22 | 2025 | 693 | 2.560 |
Why?
|
| Colonoscopy | 21 | 2026 | 265 | 2.550 |
Why?
|
| Uterine Cervical Neoplasms | 7 | 2025 | 135 | 2.450 |
Why?
|
| Humans | 113 | 2026 | 17622 | 2.280 |
Why?
|
| Survivors | 6 | 2018 | 157 | 2.270 |
Why?
|
| Breast Neoplasms | 24 | 2025 | 1005 | 2.250 |
Why?
|
| Neoplasm Recurrence, Local | 12 | 2026 | 248 | 2.180 |
Why?
|
| Cancer Survivors | 7 | 2025 | 115 | 1.940 |
Why?
|
| Aged | 73 | 2025 | 6223 | 1.920 |
Why?
|
| Female | 88 | 2026 | 12715 | 1.920 |
Why?
|
| Guideline Adherence | 5 | 2025 | 155 | 1.880 |
Why?
|
| Middle Aged | 72 | 2026 | 7954 | 1.860 |
Why?
|
| Male | 54 | 2026 | 10014 | 1.460 |
Why?
|
| Electronic Health Records | 7 | 2023 | 719 | 1.410 |
Why?
|
| Occult Blood | 13 | 2024 | 162 | 1.400 |
Why?
|
| Adult | 37 | 2026 | 7621 | 1.380 |
Why?
|
| Quality of Life | 5 | 2026 | 505 | 1.360 |
Why?
|
| Uterine Cervical Dysplasia | 4 | 2025 | 10 | 1.360 |
Why?
|
| Algorithms | 5 | 2020 | 227 | 1.350 |
Why?
|
| Psychometrics | 2 | 2026 | 119 | 1.350 |
Why?
|
| Papillomavirus Infections | 4 | 2025 | 144 | 1.330 |
Why?
|
| Postmenopause | 11 | 2009 | 251 | 1.260 |
Why?
|
| Health Services Research | 4 | 2016 | 201 | 1.240 |
Why?
|
| Adaptation, Psychological | 4 | 2018 | 79 | 1.180 |
Why?
|
| Colposcopy | 3 | 2025 | 6 | 1.170 |
Why?
|
| Risk Factors | 23 | 2026 | 3291 | 1.060 |
Why?
|
| United States | 21 | 2025 | 3922 | 1.060 |
Why?
|
| Washington | 19 | 2020 | 388 | 1.020 |
Why?
|
| Animal Assisted Therapy | 2 | 2017 | 5 | 0.990 |
Why?
|
| Aged, 80 and over | 22 | 2024 | 1976 | 0.980 |
Why?
|
| Child, Hospitalized | 2 | 2017 | 15 | 0.980 |
Why?
|
| Lung Neoplasms | 4 | 2025 | 278 | 0.940 |
Why?
|
| Antidepressive Agents | 3 | 2015 | 142 | 0.930 |
Why?
|
| Anti-Bacterial Agents | 2 | 2026 | 152 | 0.930 |
Why?
|
| Young Adult | 18 | 2026 | 2538 | 0.910 |
Why?
|
| Adenoma | 7 | 2024 | 98 | 0.880 |
Why?
|
| Surveys and Questionnaires | 11 | 2026 | 1296 | 0.840 |
Why?
|
| Papillomavirus Vaccines | 1 | 2025 | 114 | 0.820 |
Why?
|
| Retrospective Studies | 18 | 2026 | 2502 | 0.810 |
Why?
|
| Practice Guidelines as Topic | 7 | 2025 | 319 | 0.810 |
Why?
|
| Comparative Effectiveness Research | 3 | 2013 | 59 | 0.770 |
Why?
|
| Epidemiologic Methods | 2 | 2012 | 70 | 0.730 |
Why?
|
| Exercise | 8 | 2008 | 538 | 0.710 |
Why?
|
| Predictive Value of Tests | 5 | 2026 | 346 | 0.700 |
Why?
|
| Bias | 4 | 2022 | 95 | 0.700 |
Why?
|
| Diabetes Mellitus | 2 | 2018 | 452 | 0.700 |
Why?
|
| Reproducibility of Results | 3 | 2026 | 363 | 0.700 |
Why?
|
| Colonic Neoplasms | 2 | 2019 | 164 | 0.660 |
Why?
|
| Adolescent | 13 | 2026 | 3625 | 0.650 |
Why?
|
| Neoplasms, Second Primary | 4 | 2018 | 33 | 0.650 |
Why?
|
| Delivery of Health Care, Integrated | 8 | 2017 | 540 | 0.640 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2022 | 380 | 0.610 |
Why?
|
| Return to Work | 1 | 2019 | 2 | 0.610 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2019 | 6 | 0.610 |
Why?
|
| Follow-Up Studies | 10 | 2020 | 1157 | 0.610 |
Why?
|
| Adenocarcinoma | 4 | 2022 | 172 | 0.590 |
Why?
|
| Proportional Hazards Models | 6 | 2019 | 702 | 0.580 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2019 | 56 | 0.580 |
Why?
|
| Time Factors | 7 | 2019 | 1038 | 0.560 |
Why?
|
| Age Factors | 5 | 2024 | 874 | 0.550 |
Why?
|
| Liver Cirrhosis | 1 | 2017 | 31 | 0.520 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2017 | 22 | 0.520 |
Why?
|
| Sensitivity and Specificity | 6 | 2022 | 302 | 0.520 |
Why?
|
| Health Expenditures | 1 | 2018 | 72 | 0.510 |
Why?
|
| Liver Neoplasms | 1 | 2017 | 36 | 0.510 |
Why?
|
| Cohort Studies | 14 | 2025 | 2502 | 0.500 |
Why?
|
| Case-Control Studies | 9 | 2026 | 1107 | 0.490 |
Why?
|
| Anticarcinogenic Agents | 1 | 2016 | 13 | 0.480 |
Why?
|
| Cardiovascular Diseases | 4 | 2025 | 545 | 0.480 |
Why?
|
| Feces | 2 | 2016 | 89 | 0.480 |
Why?
|
| Patient Satisfaction | 1 | 2017 | 193 | 0.480 |
Why?
|
| Registries | 9 | 2026 | 475 | 0.470 |
Why?
|
| Employment | 1 | 2016 | 44 | 0.470 |
Why?
|
| Oncology Service, Hospital | 1 | 2015 | 1 | 0.470 |
Why?
|
| Bonding, Human-Pet | 1 | 2015 | 2 | 0.470 |
Why?
|
| Endometrial Neoplasms | 2 | 2007 | 37 | 0.470 |
Why?
|
| Colonic Polyps | 3 | 2023 | 36 | 0.470 |
Why?
|
| Population Surveillance | 1 | 2017 | 248 | 0.470 |
Why?
|
| Research | 2 | 2013 | 60 | 0.470 |
Why?
|
| Primary Prevention | 1 | 2016 | 61 | 0.470 |
Why?
|
| Paroxetine | 1 | 2015 | 14 | 0.470 |
Why?
|
| Aspirin | 1 | 2016 | 63 | 0.470 |
Why?
|
| Mammography | 3 | 2015 | 173 | 0.460 |
Why?
|
| Insurance Coverage | 1 | 2016 | 99 | 0.460 |
Why?
|
| Insurance, Health | 1 | 2016 | 169 | 0.440 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 308 | 0.430 |
Why?
|
| Antidepressive Agents, Tricyclic | 2 | 2013 | 8 | 0.430 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2012 | 53 | 0.420 |
Why?
|
| Delivery of Health Care | 6 | 2022 | 383 | 0.410 |
Why?
|
| Professional Role | 1 | 2013 | 14 | 0.410 |
Why?
|
| Depressive Disorder | 1 | 2015 | 186 | 0.410 |
Why?
|
| Epidemiologic Studies | 1 | 2013 | 29 | 0.400 |
Why?
|
| Medical Oncology | 1 | 2013 | 33 | 0.400 |
Why?
|
| Preventive Medicine | 1 | 2013 | 22 | 0.390 |
Why?
|
| Behavioral Sciences | 1 | 2012 | 4 | 0.380 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 121 | 0.380 |
Why?
|
| Papillomaviridae | 4 | 2025 | 61 | 0.370 |
Why?
|
| Reminder Systems | 5 | 2017 | 76 | 0.370 |
Why?
|
| California | 8 | 2026 | 2433 | 0.370 |
Why?
|
| Health Personnel | 1 | 2013 | 135 | 0.370 |
Why?
|
| Health Status Indicators | 1 | 2012 | 60 | 0.360 |
Why?
|
| Heart Diseases | 1 | 2012 | 71 | 0.360 |
Why?
|
| Incidence | 7 | 2026 | 1278 | 0.360 |
Why?
|
| Health Policy | 1 | 2012 | 106 | 0.360 |
Why?
|
| Logistic Models | 6 | 2018 | 866 | 0.330 |
Why?
|
| Serotonin Uptake Inhibitors | 1 | 2011 | 45 | 0.330 |
Why?
|
| Databases, Factual | 1 | 2011 | 304 | 0.320 |
Why?
|
| Animals | 3 | 2017 | 285 | 0.310 |
Why?
|
| Postal Service | 5 | 2019 | 72 | 0.310 |
Why?
|
| Estrogen Replacement Therapy | 2 | 2007 | 100 | 0.310 |
Why?
|
| Drug Prescriptions | 1 | 2011 | 143 | 0.310 |
Why?
|
| Histamine H2 Antagonists | 1 | 2009 | 13 | 0.300 |
Why?
|
| Proton Pump Inhibitors | 1 | 2009 | 24 | 0.290 |
Why?
|
| Patient Compliance | 4 | 2017 | 269 | 0.290 |
Why?
|
| Disease Progression | 3 | 2016 | 266 | 0.290 |
Why?
|
| Odds Ratio | 7 | 2019 | 631 | 0.290 |
Why?
|
| Health Care Costs | 1 | 2010 | 211 | 0.290 |
Why?
|
| Gonadal Steroid Hormones | 2 | 2005 | 27 | 0.280 |
Why?
|
| Age of Onset | 2 | 2026 | 74 | 0.280 |
Why?
|
| Breast | 1 | 2009 | 85 | 0.280 |
Why?
|
| Longitudinal Studies | 4 | 2025 | 686 | 0.280 |
Why?
|
| Research Design | 5 | 2013 | 337 | 0.270 |
Why?
|
| Estrogens | 2 | 2007 | 60 | 0.270 |
Why?
|
| Progestins | 1 | 2007 | 25 | 0.260 |
Why?
|
| Hypertension | 2 | 2025 | 486 | 0.260 |
Why?
|
| Common Cold | 1 | 2006 | 2 | 0.250 |
Why?
|
| Dogs | 2 | 2017 | 19 | 0.250 |
Why?
|
| Thinness | 1 | 2006 | 31 | 0.240 |
Why?
|
| Hospitals, Pediatric | 2 | 2017 | 73 | 0.240 |
Why?
|
| Hodgkin Disease | 1 | 2025 | 4 | 0.240 |
Why?
|
| Bone Density | 1 | 2006 | 96 | 0.240 |
Why?
|
| Thyroid Neoplasms | 1 | 2025 | 15 | 0.230 |
Why?
|
| Cost-Benefit Analysis | 2 | 2024 | 237 | 0.230 |
Why?
|
| Neoplasm Staging | 7 | 2017 | 350 | 0.230 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2018 | 65 | 0.230 |
Why?
|
| Trastuzumab | 1 | 2025 | 19 | 0.230 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2025 | 10 | 0.230 |
Why?
|
| Overweight | 5 | 2007 | 266 | 0.220 |
Why?
|
| SEER Program | 5 | 2020 | 92 | 0.220 |
Why?
|
| Patient Navigation | 2 | 2015 | 20 | 0.220 |
Why?
|
| Anxiety | 2 | 2018 | 162 | 0.220 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2004 | 3 | 0.220 |
Why?
|
| Risk Assessment | 5 | 2019 | 1093 | 0.220 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2025 | 60 | 0.220 |
Why?
|
| Estradiol | 1 | 2004 | 23 | 0.210 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2004 | 21 | 0.210 |
Why?
|
| Patient-Centered Care | 2 | 2016 | 190 | 0.200 |
Why?
|
| Health Status | 1 | 2005 | 291 | 0.200 |
Why?
|
| Vaginal Smears | 4 | 2025 | 48 | 0.200 |
Why?
|
| Biomarkers, Tumor | 1 | 2004 | 148 | 0.200 |
Why?
|
| Ovarian Neoplasms | 2 | 2014 | 53 | 0.190 |
Why?
|
| Survival Rate | 2 | 2013 | 252 | 0.190 |
Why?
|
| Primary Health Care | 3 | 2022 | 729 | 0.190 |
Why?
|
| Cross-Sectional Studies | 4 | 2024 | 1295 | 0.180 |
Why?
|
| Reproductive History | 2 | 2017 | 17 | 0.180 |
Why?
|
| Linear Models | 4 | 2011 | 204 | 0.160 |
Why?
|
| Tamoxifen | 2 | 2018 | 55 | 0.160 |
Why?
|
| Obesity | 5 | 2007 | 821 | 0.160 |
Why?
|
| Confounding Factors (Epidemiology) | 2 | 2013 | 82 | 0.160 |
Why?
|
| Intestinal Polyps | 1 | 2020 | 7 | 0.160 |
Why?
|
| Prostatic Neoplasms | 1 | 2022 | 262 | 0.160 |
Why?
|
| Patient Selection | 2 | 2012 | 181 | 0.160 |
Why?
|
| Vaccination | 1 | 2025 | 726 | 0.160 |
Why?
|
| Confidence Intervals | 4 | 2013 | 228 | 0.160 |
Why?
|
| Interviews as Topic | 2 | 2013 | 324 | 0.150 |
Why?
|
| Symptom Assessment | 1 | 2019 | 6 | 0.150 |
Why?
|
| Child | 2 | 2017 | 2485 | 0.150 |
Why?
|
| Socioeconomic Factors | 3 | 2019 | 603 | 0.150 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2018 | 1 | 0.150 |
Why?
|
| Educational Status | 1 | 2019 | 177 | 0.150 |
Why?
|
| Motivation | 1 | 2019 | 112 | 0.140 |
Why?
|
| Treatment Outcome | 6 | 2015 | 1161 | 0.140 |
Why?
|
| Evidence-Based Medicine | 1 | 2019 | 173 | 0.140 |
Why?
|
| Diabetes Complications | 1 | 2018 | 103 | 0.140 |
Why?
|
| Healthcare Disparities | 2 | 2019 | 208 | 0.130 |
Why?
|
| Ultrasonography | 1 | 2017 | 34 | 0.130 |
Why?
|
| Pediatric Nursing | 1 | 2017 | 4 | 0.130 |
Why?
|
| Nurses | 2 | 2015 | 33 | 0.130 |
Why?
|
| Comorbidity | 2 | 2016 | 552 | 0.130 |
Why?
|
| Contraceptives, Oral | 1 | 2017 | 25 | 0.130 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2016 | 16 | 0.120 |
Why?
|
| Pilot Projects | 1 | 2017 | 214 | 0.120 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 258 | 0.120 |
Why?
|
| Androgens | 2 | 2008 | 14 | 0.120 |
Why?
|
| Genetic Counseling | 2 | 2014 | 27 | 0.120 |
Why?
|
| Specimen Handling | 1 | 2016 | 25 | 0.120 |
Why?
|
| Utah | 2 | 2025 | 38 | 0.120 |
Why?
|
| Risk | 2 | 2015 | 492 | 0.120 |
Why?
|
| Antihypertensive Agents | 1 | 2017 | 163 | 0.120 |
Why?
|
| Medical Records | 1 | 2015 | 91 | 0.110 |
Why?
|
| Health Surveys | 1 | 2016 | 242 | 0.110 |
Why?
|
| Hypoglycemic Agents | 1 | 2017 | 259 | 0.110 |
Why?
|
| Inpatients | 1 | 2015 | 78 | 0.110 |
Why?
|
| Testosterone | 2 | 2005 | 21 | 0.110 |
Why?
|
| Outpatients | 1 | 2015 | 103 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2014 | 323 | 0.110 |
Why?
|
| Prognosis | 3 | 2015 | 609 | 0.110 |
Why?
|
| Aromatase | 2 | 2004 | 9 | 0.110 |
Why?
|
| Adipose Tissue | 2 | 2004 | 67 | 0.100 |
Why?
|
| Depressive Disorder, Major | 1 | 2015 | 98 | 0.100 |
Why?
|
| Self Efficacy | 1 | 2014 | 69 | 0.100 |
Why?
|
| Cardiovascular Agents | 1 | 2014 | 22 | 0.100 |
Why?
|
| Patient Advocacy | 1 | 2013 | 12 | 0.100 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2013 | 9 | 0.100 |
Why?
|
| Utilization Review | 1 | 2013 | 42 | 0.100 |
Why?
|
| Observer Variation | 1 | 2013 | 36 | 0.100 |
Why?
|
| Selection Bias | 1 | 2013 | 16 | 0.100 |
Why?
|
| Patient Care Planning | 1 | 2013 | 45 | 0.100 |
Why?
|
| Observation | 1 | 2013 | 20 | 0.100 |
Why?
|
| Counseling | 1 | 2015 | 173 | 0.100 |
Why?
|
| Societies, Medical | 1 | 2013 | 71 | 0.100 |
Why?
|
| Continuity of Patient Care | 2 | 2011 | 95 | 0.100 |
Why?
|
| Health Promotion | 1 | 2016 | 293 | 0.100 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2013 | 23 | 0.100 |
Why?
|
| Patient Preference | 1 | 2013 | 49 | 0.100 |
Why?
|
| Recurrence | 1 | 2013 | 166 | 0.100 |
Why?
|
| Effect Modifier, Epidemiologic | 1 | 2012 | 8 | 0.100 |
Why?
|
| Survival Analysis | 1 | 2013 | 197 | 0.100 |
Why?
|
| Translational Medical Research | 1 | 2012 | 32 | 0.090 |
Why?
|
| Outcome and Process Assessment (Health Care) | 1 | 2012 | 96 | 0.090 |
Why?
|
| Ovariectomy | 1 | 2012 | 9 | 0.090 |
Why?
|
| Clinical Coding | 1 | 2011 | 11 | 0.090 |
Why?
|
| Pandemics | 2 | 2025 | 295 | 0.090 |
Why?
|
| Program Evaluation | 1 | 2012 | 214 | 0.090 |
Why?
|
| Drug Administration Schedule | 2 | 2012 | 99 | 0.090 |
Why?
|
| Specialization | 1 | 2011 | 21 | 0.090 |
Why?
|
| Weight Loss | 2 | 2022 | 298 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2017 | 689 | 0.080 |
Why?
|
| False Positive Reactions | 1 | 2010 | 26 | 0.080 |
Why?
|
| Depression | 1 | 2015 | 507 | 0.080 |
Why?
|
| Medication Adherence | 1 | 2012 | 232 | 0.080 |
Why?
|
| Anti-Ulcer Agents | 1 | 2009 | 5 | 0.080 |
Why?
|
| Ambulatory Care | 1 | 2011 | 228 | 0.080 |
Why?
|
| Phenotype | 2 | 2020 | 154 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2009 | 63 | 0.070 |
Why?
|
| Health Behavior | 2 | 2012 | 348 | 0.070 |
Why?
|
| Prospective Studies | 1 | 2012 | 1251 | 0.070 |
Why?
|
| Telephone | 3 | 2017 | 159 | 0.070 |
Why?
|
| Referral and Consultation | 1 | 2009 | 161 | 0.070 |
Why?
|
| Carcinoma, Lobular | 1 | 2007 | 10 | 0.070 |
Why?
|
| Sigmoidoscopy | 3 | 2013 | 65 | 0.070 |
Why?
|
| Catechol O-Methyltransferase | 2 | 2004 | 2 | 0.070 |
Why?
|
| Pregnancy | 2 | 2023 | 1565 | 0.070 |
Why?
|
| Chronic Disease | 2 | 2025 | 398 | 0.070 |
Why?
|
| Prolactin | 1 | 2007 | 4 | 0.070 |
Why?
|
| Medicare | 2 | 2017 | 197 | 0.060 |
Why?
|
| Respiratory Tract Infections | 1 | 2006 | 59 | 0.060 |
Why?
|
| Lipoproteins | 1 | 2006 | 13 | 0.060 |
Why?
|
| Neoplasm Metastasis | 1 | 2026 | 35 | 0.060 |
Why?
|
| Multivariate Analysis | 1 | 2007 | 527 | 0.060 |
Why?
|
| Androstenedione | 1 | 2005 | 3 | 0.060 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2005 | 6 | 0.060 |
Why?
|
| Dehydroepiandrosterone | 1 | 2005 | 7 | 0.060 |
Why?
|
| Outcome Assessment (Health Care) | 2 | 2017 | 213 | 0.060 |
Why?
|
| Phytotherapy | 1 | 2005 | 12 | 0.060 |
Why?
|
| Global Health | 1 | 2025 | 28 | 0.060 |
Why?
|
| Cluster Analysis | 1 | 2025 | 90 | 0.060 |
Why?
|
| Exercise Therapy | 1 | 2006 | 75 | 0.060 |
Why?
|
| Texas | 1 | 2025 | 41 | 0.060 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2024 | 41 | 0.050 |
Why?
|
| Menstrual Cycle | 1 | 2004 | 5 | 0.050 |
Why?
|
| Body Mass Index | 5 | 2007 | 959 | 0.050 |
Why?
|
| Probability | 1 | 2004 | 70 | 0.050 |
Why?
|
| Parity | 1 | 2004 | 57 | 0.050 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2004 | 5 | 0.050 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 1 | 2004 | 5 | 0.050 |
Why?
|
| Age Distribution | 1 | 2004 | 230 | 0.050 |
Why?
|
| Polymorphism, Genetic | 1 | 2004 | 61 | 0.050 |
Why?
|
| Office Visits | 2 | 2016 | 75 | 0.050 |
Why?
|
| Influenza Vaccines | 1 | 2006 | 301 | 0.050 |
Why?
|
| Papanicolaou Test | 1 | 2022 | 38 | 0.050 |
Why?
|
| Prostate-Specific Antigen | 1 | 2022 | 74 | 0.050 |
Why?
|
| Self Report | 2 | 2013 | 262 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2014 | 384 | 0.040 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2020 | 15 | 0.040 |
Why?
|
| Data Warehousing | 1 | 2020 | 3 | 0.040 |
Why?
|
| DNA Methylation | 1 | 2020 | 45 | 0.040 |
Why?
|
| Medical History Taking | 1 | 2019 | 33 | 0.040 |
Why?
|
| Mutation | 1 | 2020 | 133 | 0.040 |
Why?
|
| Financial Support | 1 | 2019 | 6 | 0.040 |
Why?
|
| Biopsy | 1 | 2019 | 80 | 0.040 |
Why?
|
| Demography | 1 | 2019 | 92 | 0.040 |
Why?
|
| Cytochrome P-450 CYP2D6 Inhibitors | 1 | 2018 | 1 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2018 | 55 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2014 | 368 | 0.040 |
Why?
|
| Attitude to Health | 1 | 2019 | 147 | 0.030 |
Why?
|
| Sulfonylurea Compounds | 1 | 2017 | 32 | 0.030 |
Why?
|
| Metformin | 1 | 2017 | 52 | 0.030 |
Why?
|
| Insulin | 1 | 2017 | 188 | 0.030 |
Why?
|
| Aftercare | 1 | 2016 | 47 | 0.030 |
Why?
|
| Family Health | 1 | 2014 | 45 | 0.030 |
Why?
|
| Alleles | 2 | 2004 | 80 | 0.030 |
Why?
|
| Genotype | 2 | 2004 | 224 | 0.030 |
Why?
|
| Sex Factors | 1 | 2015 | 599 | 0.030 |
Why?
|
| Idaho | 1 | 2013 | 24 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2013 | 65 | 0.020 |
Why?
|
| Aromatase Inhibitors | 1 | 2012 | 33 | 0.020 |
Why?
|
| Treatment Refusal | 1 | 2012 | 30 | 0.020 |
Why?
|
| Residence Characteristics | 1 | 2014 | 256 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2012 | 268 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2011 | 137 | 0.020 |
Why?
|
| Nursing Care | 1 | 2010 | 4 | 0.020 |
Why?
|
| Nursing Staff, Hospital | 1 | 2010 | 10 | 0.020 |
Why?
|
| Sample Size | 1 | 2010 | 27 | 0.020 |
Why?
|
| Quality Control | 1 | 2010 | 40 | 0.020 |
Why?
|
| Allied Health Personnel | 1 | 2010 | 12 | 0.020 |
Why?
|
| Continental Population Groups | 1 | 2012 | 283 | 0.020 |
Why?
|
| Data Collection | 1 | 2010 | 234 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 2008 | 9 | 0.020 |
Why?
|
| Adiposity | 1 | 2008 | 71 | 0.020 |
Why?
|
| Long-Term Care | 1 | 2007 | 22 | 0.020 |
Why?
|
| Feeding Behavior | 1 | 2007 | 163 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 2004 | 4 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2004 | 51 | 0.010 |
Why?
|
| DNA | 1 | 2004 | 26 | 0.010 |
Why?
|
| Cytochrome P-450 CYP1B1 | 1 | 2004 | 2 | 0.010 |
Why?
|
| Body Composition | 1 | 2004 | 92 | 0.010 |
Why?
|
| Body Weight | 1 | 2004 | 203 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2004 | 215 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2004 | 369 | 0.010 |
Why?
|